ASH 2018 | Novel anti-CD123 antibody-drug conjugate IMGN632 for R/R AML shows promise
CD123 is an attractive therapeutic target in a number fo hematological malignancies due to its overexpression. Here, Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, reports the promising initial safety and efficacy data from the dose escalation stage of the first-in-human trial of IMGN632, an anti-CD123 antibody-drug conjugate. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up